USH3AL1 Inhibitors
USH3AL1 Inhibitors consist of a variety of chemical compounds that can indirectly suppress the functional activity of USH3AL1 by targeting specific signaling pathways or cellular processes with which USH3AL1 may be associated. For instance, Erlotinib, an EGFR inhibitor, can disrupt EGFR signaling pathways that are potentially upstream of USH3AL1, leading to its functional inhibition. Similarly, Rapamycin and LY294002, as mTOR and PI3K inhibitors respectively, can decrease the functional activity of USH3AL1 by inhibiting pathways crucial for protein synthesis and cellular growth, as well as the PI3K-Akt signaling pathway, which might intersect with the biological processes involving USH3AL1. Other inhibitors that target the MAPK/ERK pathway, such as U0126 and PD98059, can also impede the processes in which USH3AL1 is implicated, by preventing the phosphorylation and activation of kinases that could regulate USH3AL1's activity.
Further, compounds like SB203580 and Sorafenib, which inhibit p38 MAPK and RAF kinases respectively, could hinder the functional activity of USH3AL1. The inhibition of these kinases might affect the signaling events relevant to USH3AL1's role within the cell. Additionally, inhibitors like Imatinib and SP600125, which target tyrosine kinases and JNK, respectively, could also result in the downregulation of USH3AL1 by altering the signaling mechanisms that USH3AL1 may participate in.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor that could indirectly inhibit USH3AL1 by blocking EGFR signaling which may be upstream of USH3AL1's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that could lead to the downregulation of USH3AL1 by inhibiting the mTOR pathway, which is involved in protein synthesis and cellular growth. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could decrease the functional activity of USH3AL1 by inhibiting PI3K-Akt signaling, possibly affecting pathways that USH3AL1 is part of. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that could reduce the functional activity of USH3AL1 through the inhibition of the MAPK/ERK pathway, potentially affecting the cellular processes USH3AL1 is involved in. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that might lead to the functional inhibition of USH3AL1 by blocking the p38 MAPK signaling pathway, which could intersect with USH3AL1's role in the cell. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a RAF kinase inhibitor that could inhibit USH3AL1 indirectly by targeting the RAF/MEK/ERK pathway, possibly influencing processes USH3AL1 is involved in. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that could decrease USH3AL1 activity by inhibiting BCR-ABL and other tyrosine kinases, potentially affecting USH3AL1-related pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that could decrease USH3AL1 activity by inhibiting JNK signaling, which may impact cellular processes involving USH3AL1. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
WZ4003 is a NUAK1 inhibitor that could indirectly inhibit USH3AL1 by blocking NUAK1, a kinase that may interact with pathways involving USH3AL1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that could reduce USH3AL1 activity by inhibiting the MAPK/ERK pathway, which may be relevant to the function of USH3AL1 in cells. | ||||||